A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Recombinant Botulinum Toxin Type a (JHM03) in Adult Patients with Upper Limb Spasticity
Latest Information Update: 06 Sep 2024
At a glance
- Drugs JHM 03 (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- Sponsors JHM BioPharma (Tonghua)
- 06 Sep 2024 New trial record